Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Small Lymphocytic Lymphoma With 17p Deletion”

8 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 8 of 8 results

Testing effectiveness (Phase 2)Study completedNCT02337829
What this trial is testing

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Acerta Pharma BV 48
Large-scale testing (Phase 3)Study completedNCT03406156
What this trial is testing

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Who this might be right for
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
AbbVie 120
Testing effectiveness (Phase 2)Study completedNCT01744691
What this trial is testing

Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion

Who this might be right for
Chronic Lymphocytic Leukemia With 17p DeletionSmall Lymphocytic Lymphoma With 17p Deletion
Pharmacyclics LLC. 145
Testing effectiveness (Phase 2)Study completedNCT01527045
What this trial is testing

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

Who this might be right for
Aggressive Non-Hodgkin LymphomaBlasts Under 5 Percent of Bone Marrow Nucleated CellsChronic Lymphocytic Leukemia+18 more
Fred Hutchinson Cancer Center 47
Testing effectiveness (Phase 2)Study completedNCT02420912
What this trial is testing

Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Richter Transformation

Who this might be right for
Loss of Chromosome 17pRecurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic Lymphoma+3 more
M.D. Anderson Cancer Center 37
Testing effectiveness (Phase 2)Study completedNCT01008462
What this trial is testing

Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

Who this might be right for
B-Cell Prolymphocytic LeukemiaHypodiploidyLoss of Chromosome 17p+18 more
Fred Hutchinson Cancer Center 16
Testing effectiveness (Phase 2)Looking for participantsNCT02966756
What this trial is testing

Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Who this might be right for
Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)
AbbVie 110
Testing effectiveness (Phase 2)Active Not RecruitingNCT01500733
What this trial is testing

PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Who this might be right for
LeukemiaLeukemia, LymphocytycCLL (Chronic Lymphocytic Leukemia)+1 more
National Heart, Lung, and Blood Institute (NHLBI) 86